Jardiance Tablet, Film Coated
NDC Package 71610-900-09
Package Information
Jardiance (empagliflozin) tablets is jARDIANCE is indicated:to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. This formulation utilizes a tablet, film coated delivery system. Marketed by Aphena Pharma Solutions - Tennessee, Llc, this product is identified by NDC 71610-900 and is authorized under FDA application NDA204629.
Identification & Billing
- RxCUI: 1545658 - empagliflozin 10 MG Oral Tablet
- RxCUI: 1545664 - Jardiance 10 MG Oral Tablet
- RxCUI: 1545664 - empagliflozin 10 MG Oral Tablet [Jardiance]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71610 - Aphena Pharma Solutions - Tennessee, Llc
- 71610-900 - Jardiance
- 71610-900-09 - 9000 TABLET, FILM COATED in 1 BOTTLE
- 71610-900 - Jardiance
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (71610-900). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71610-900-09 identifies a specific commercial package of 9000 tablet, film coated in 1 bottle of Jardiance, a human prescription drug labeled by Aphena Pharma Solutions - Tennessee, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 9000 billable units per package. This tablet, film coated is formulated for oral use and contains empagliflozin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aphena Pharma Solutions - Tennessee, Llc on August 01, 2014. The current certification is valid through December 31, 2027.
How is this Aphena Pharma Solutions - Tennessee, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71610090009. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 9000 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.